<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02011880</url>
  </required_header>
  <id_info>
    <org_study_id>ZYSNXD-CC-ZDYJ043</org_study_id>
    <nct_id>NCT02011880</nct_id>
  </id_info>
  <brief_title>Standardization Research of TCM Syndrome Differentiation and Treatment on Advanced Breast Cancer</brief_title>
  <official_title>Standardization Research of TCM Syndrome Differentiation and Treatment on Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to learn if the clinical effects of combined&#xD;
      Chinese herbal medicine with endocrine therapy is better than endocrine therapy alone in&#xD;
      improving the quality of life and shrinking and slowing the growth of the cancer in women&#xD;
      with breast cancer bone metastasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Evaluate the effect of the Chinese herbal medicine on relieving the bone pain for&#xD;
           patients with breast cancer bone metastasis.&#xD;
&#xD;
        -  Evaluate the effect of the Chinese herbal medicine on improving the quality of life and&#xD;
           shrinking and slowing the growth of the cancer in women with breast cancer bone&#xD;
           metastasis.&#xD;
&#xD;
      OUTLINE: This is a randomized,multicentric, placebo-controlled, double-blind study. Patients&#xD;
      are dynamic randomized to one of two treatment arms.&#xD;
&#xD;
        -  Arm I:Patients receive traditional Chinese medicine(trial drugs) and endocrine therapy&#xD;
           for 3 months.&#xD;
&#xD;
        -  Arm II:Patients receive placebo and endocrine therapy for 3 months. All patients will be&#xD;
           followed up for another 3 months with the trial drugs and endocrine therapy.&#xD;
&#xD;
      According to the sample size estimate:There are 296 patients (148 per treatment arm)will be&#xD;
      collected in this trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Temporarily not available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Breast Cancer</condition>
  <condition>Bone Metastasis</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Chinese Herbs</intervention_name>
    <description>Dietary Supplement:Experiment group:&#xD;
Fructus Cnidii,Psoralea Corylifolin L.，monkshood&#xD;
-Granules,Oral(add into the breast cancer postoperative prescription solution),A Pack(Fructus Cnidii 9g，Psoralea Corylifolin L. 15g，monkshood 9g),Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity&#xD;
Breast Cancer Postoperative Prescription&#xD;
-Water Decoction,Oral,200ml,Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity&#xD;
Dietary Supplement:Contrast Group:&#xD;
Breast Cancer Postoperative Prescription&#xD;
-Water Decoction,Oral,200ml,Bid Days,3 Periods( a month is a period),Until progression/unacceptable toxicity</description>
    <other_name>Fructus Cnidii</other_name>
    <other_name>Psoralea Corylifolin L.</other_name>
    <other_name>monkhsood</other_name>
    <other_name>Breast Cancer Postoperative Prescription</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed breast cancer and hormone receptor positive.&#xD;
&#xD;
          -  Bone metastasis and have a measurable foci.&#xD;
&#xD;
          -  TCM syndrome type is deficiency of both vital energy and Yin ;maladjustment of&#xD;
             ChongRen with deficiency Yang syndrome.&#xD;
&#xD;
          -  The Karnofsky score ≥60.&#xD;
&#xD;
          -  VAS score ≥3.&#xD;
&#xD;
          -  Expected survival at least 6 months or greater.&#xD;
&#xD;
          -  Age between 20 to 70(include 20 and 70).&#xD;
&#xD;
          -  The function of cardiovascular,hepar,renal and hematopoieses is relatively normal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women during the pregnancy or breast feeding.&#xD;
&#xD;
          -  With a cardiovascular,hepar,renal,hematopoieses or other serious complications.&#xD;
&#xD;
          -  Be allergic to the trial drugs.&#xD;
&#xD;
          -  Participating in other trials.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>December 10, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2013</study_first_posted>
  <last_update_submitted>December 10, 2013</last_update_submitted>
  <last_update_submitted_qc>December 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>bone metastasis</keyword>
  <keyword>traditional Chinese medicine(TCM)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corylifolin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

